TITLE

In Search of Safer NSAIDs: Which Cause the Least Risk of Upper GI Bleeding?

AUTHOR(S)
Scherger, Joseph E.
PUB. DATE
August 2010
SOURCE
Internal Medicine Alert;8/15/2010, Vol. 32 Issue 15, p115
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
A systematic review of 9 studies showed that the COX-2 inhibitor celecoxib and ibufrofen cause less upper GI bleeding than other NSAIDs. Diclofenac meloxicam, ketoprofen, indomethacin, and naproxen have intermediate risk. Piroxicam and ketorolac have the highest risk. In general, drugs that have a long half-life or slow-release formulation have the greatest risk of GI bleeding.
ACCESSION #
53751407

 

Related Articles

  • Celecoxib No Safer Than Naproxen for Peptic Ulcer. Shaughnessy, Allen F. // American Family Physician;4/15/2006, Vol. 73 Issue 8, p1446 

    Discusses research on the efficacy of celecoxib versus lansoprazole and naproxen in preventing gastrointestinal ulcer complications. Reference to a study by K. C. Lai et al, published in the November 2005 issue of the "American Journal of Medicine"; Background on the study subjects; Details of...

  • Celecoxib Is as Effective as Diclofenac plus Omeprazole at Reducing Ulcer Bleeding. Chan, F. K;; Hung, L. C.; Suen, B. Y. // Annals of Internal Medicine;9/7/2004, Vol. 141 Issue 5, p375 

    This article presents information on effectiveness of various drugs used to treat ulcer bleeding. Current guidelines recommend that patients who are at risk for ulcer disease and require treatment for arthritis should receive either a cyclooxygenase-2 (COX-2) drug or a nonselective nonsteroidal...

  • Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis. Fleischmann, Roy; Tannenbaum, Hyman; Patel, Neha P.; Notter, Marianne; Sallstig, Peter; Reginster, Jean-Yves // BMC Musculoskeletal Disorders;2008, Vol. 9, Special section p1 

    Background: The efficacy, safety and tolerability of lumiracoxib, a novel selective cyclooxygenase-2 (COX-2) inhibitor, has been demonstrated in previous studies of patients with osteoarthritis (OA). As it is important to establish the long-term safety and efficacy of treatments for a chronic...

  • Renal effects of cyclooxygenase inhibitors in volume-depleted dogs. Brooks, David P.; Adams, Jerry; DePalma, P. Dennis; Webb, Edward F.; Palmer, Robert H.; Griswold, Don E. // Inflammopharmacology;2000, Vol. 8 Issue 1, p69 

    Objective: The objective of this study was to investigate the renal effects of celecoxib, a cyclooxygenase-2 (COX-2) specific nonsteroidal anti-inflammatory drug (NSAID). Subjects and treatment: Six volume-depleted, conscious, chronically instrumented dogs received four treatments using a...

  • Celecoxib and rofecoxib. Moore, Paul A.; Hersh, Elliot V. // Journal of the American Dental Association (JADA);Apr2001, Vol. 132 Issue 4, p451 

    Reports on the development of the nonsteroidal anti-inflammatory drugs (NSAID), celecoxib and rofecoxib, to limit the adverse effects seen after chronic use of NSAID. Cyclo-oxygenase mechanism; Specific cyclo-oxygenase 2 inhibitors; Decrease in the antihypertensive effects of...

  • Celecoxib. O'Rourke, Maureen E. // Clinical Journal of Oncology Nursing;May/Jun2000, Vol. 4 Issue 3, p143 

    Provides information on Celecoxib, a nonsteroidal anti-inflammatory drug and a cyclooxygenase-2-inhibitor. Indications of the drug; Effect of the drug on blood count; Precautions for the drug.

  • Comparing celecoxib with traditional nonsteroidal anti-inflammatory drugs. Johnson, Melissa; Seaton, Terry // Journal of Family Practice;Feb2003, Vol. 52 Issue 2, p96 

    The article presents a study comparing the efficacy, safety and tolerability of celecoxib with other nonsteroidal anti-inflammatory drugs (NSAID) for treating osteoarthritis or rheumatoid arthritis. Celecoxib was developed to provide symptom relief without the NSAID-associated gastrointestinal...

  • Celecoxib effectively inhibits the formation of joint adhesions. FENGFENG LI; BIN HE; SHEN LIU; CUNYI FAN // Experimental & Therapeutic Medicine;2013, Vol. 6 Issue 6, p1507 

    The present study investigated the effectiveness of celecoxib in preventing the formation of joint adhesions. Rabbit models of joint adhesion were created and the rabbits in two treatment groups were orally administered celecoxib or ibuprofen (as a positive control) for 30 days. Rabbits in the...

  • Coxib medications to be handled with care. Misak, Aleksandra // CMAJ: Canadian Medical Association Journal;2/1/2005, Vol. 172 Issue 3, p330 

    Discusses the health risks of coxib medications or the cyclooxygenase-2 (COX-2) inhibitors. Increase in the risk of myocardial infarction and cerebrovascular accident in patients taking celecoxib; Indication of COX-2 inhibitors; Logic of using COX-2 inhibitors as a replacement for nonsteroidal...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics